Clarity Pharmaceuticals (ASX:CU6) said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.
The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.
Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.
The drugmaker's shares rose past 3% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.